Single-Agent Rituximab in Early-Stage Chronic Lymphocytic Leukemia

March 1, 2002
Susan O’Brien, MD

Oncology, ONCOLOGY Vol 16 No 3, Volume 16, Issue 3

Currently, patients with early-stage chronic lymphocytic leukemia (CLL) without active disease are observed. However, those patients with elevated beta-2-microglobulin levels appear to have a shorter median survival (6 years vs 10+ years).

Currently, patients with early-stage chronic lymphocytic leukemia (CLL)without active disease are observed. However, those patients with elevatedbeta-2-microglobulin levels appear to have a shorter median survival (6 years vs10+ years). Strategies designed to impact the eventual progression of diseaseinclude use of targeted therapies with minimal long-term risk. Single-agentrituximab (Rituxan) has activity in previously treated CLL (J Clin Oncol 19:2165, 2001; 19:2153, 2001) and in untreated low-grade lymphomas (Semin Oncol27:25, 2000). We designed this study to investigate the activity of rituximab inuntreated high-risk, early-stage CLL.

Patients were eligible if they had untreated Rai stage 0 to II CLL withbeta-2-microglobulin levels ³ 2.0 mg/dL, without indications for therapy according to the National CancerInstitute Working Group criteria. Rituximab was given at 375 mg/m² weekly for 8weeks. Baseline cytokine profiles known to be prognostic in CLL, includinginterleukin (IL)-6,IL-10, and tumor necrosis factor (TNF)-alpha (Blood 97:256, 2001), were obtainedwith serial measurements when feasible. Thirty-one patients have been enrolledto date; characteristics are as follows: median age, 67 years (range: 50-82years); Rai stage II in 32%; and median beta-2-microglobulin level, 3.6 mg/dL.

The overall response rate in 21 evaluable patients (eight under activetherapy, two not reassessed) was 90% (19% complete response, 19% nodular partialresponse, 48% partial response). Significant reductions in fatigue werereported. Two patients did not respond. With a median follow-up of 8 months(range: 2-16 months), one patient with partial response progressed.

No unexpected toxicities were observed; most were grade 1/2 fever, chills,and/or hypotension related to the first infusion. Samples were collected forcytokine analysis in 10 patients to date. Although the numbers were small,preliminary observations suggested reductions in TNF-alpha levels correlatedwith response.

CONCLUSION: Rituximab has significant activity in early-stage CLL. Impact onsurvival and time to progression requires longer follow-up. Furtherinvestigation of the effect of rituximab on cytokine profiles and implementationof strategies to modulate CD20 expression is planned.

Click here to read Dr. Bruce Cheson's commentary on this abstract.

Related Content:

Leukemia | Lymphoma